DIGITAL HEALTHCARE

American Rheumatology Network Announces Partnership with Augmedix to Scale Clinical Best Practices

Augmedix Inc | December 13, 2021

American Rheumatology Network (ARN), a leading national group purchasing organization for community-based rheumatology practices, announced today that they have partnered with Augmedix, Inc. (Nasdaq: AUGX), a leading digital health platform that offers virtual medical documentation and live clinical support.

ARN is a national network of over 300 community-based providers spread across 83 locations. One of ARN’s core missions is to enable its members to scale clinical best practices and obtain access to cutting edge technology optimized for rheumatology. This mission drove them to partner with Augmedix, an organization working to rehumanize healthcare using technology so that physicians can focus on what matters most: patient care.

The Augmedix partnership provides ARN members with access to Augmedix's Ambient Automation Platform (AAP). The AAP converts the natural conversation between physicians and patients into timely and comprehensive medical notes and provides a suite of related services. The medical note, overseen by trained medical documentation specialists, is generated using the AAP, which incorporates structured data models, automatic speech recognition and natural language processing.

“Augmedix has allowed me to save hours every day. It’s a tremendous boost to my quality of life, and I’m excited to see this innovative service begin to scale to my colleagues across the Network,” said Dr. Colin Edgerton, an ARN member. “I’ve been using Augmedix for 7 years; their technology and operations are impressive and continue to improve with every year that goes by.”

“From day one, we’ve been committed to complex specialty care. We’re truly excited by this new partnership as it will provide us a direct pathway into a national network of rheumatology practices. Furthermore, we are especially eager to partner with ARN due to their unique focus on innovation. Together, we are working on a rich innovation roadmap to deploy Augmedix in custom ways so that Augmedix-generated documentation and data structuring can improve clinical outcomes.”

Manny Krakaris, Chief Executive Officer at Augmedix

About Augmedix
Augmedix, Inc. is a leading digital health platform that offers virtual medical documentation and live clinical support to large healthcare systems and physician practices, supporting medical offices, clinics, hospitals, emergency departments and telemedicine practices nationwide. The Company’s Ambient Automation Platform converts the natural conversation between physicians and patients into timely and comprehensive medical notes and provides a suite of related services. The medical note is generated using Augmedix’s proprietary platform, which incorporates structured data models, automatic speech recognition and natural language processing and is overseen by trained medical documentation specialists. Augmedix saves physicians up to 3 hours per day, improves productivity by as much as 20%, and increases satisfaction with work-life balance by over 40%. 

About American Rheumatology Network
American Rheumatology Network (ARN) is a physician-led and owned organization committed to partnering with and empowering community-based rheumatology practices by providing innovative solutions to optimize patient outcomes. 

Spotlight

Check out more information about the Medical Residency and m Cancerolog i Cl inica in http://bit.ly/1MbehkV . It is the opportunity to have Einstein expertise in your resume. Join!


Other News
MEDICAL DEVICES

BD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing

BD | December 22, 2021

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in smartphone-enabled at-home medical tests.BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor™ At-Home COVID-19 Test, the first at-home COVID-19 test that uniquely uses a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. Scanwell will become the foundational digital platform upon which BD plans to develop at-home diagnostic tests for a range of infectious diseases including COVID-19/influenza A+B, group A strep and additional menu for detecting infections and managing chronic disease. "The COVID-19 pandemic has accelerated the shift to new care settings, and BD is ready to deliver a smart, connected at-home diagnostic ecosystem to support traditional and telehealth providers and consumers. This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future." Dave Hickey, president of Life Sciences for BD The Scanwell app is a key differentiator in the market for at-home COVID-19 testing. To date, no other company uses the phone's camera to capture the image of the test that is then analyzed and interpreted by the app. Other COVID-19 home tests use smartphones as part of their process, but BD Veritor™ At-Home COVID-19 Test is the first and only test to use the smartphone as the analyzer to digitally interpret the test results and provide a definitive POSITIVE or NEGATIVE digital display of testing results. The app also has the capabilities to securely store and report test results to organizations, including businesses, public health authorities and schools. The results of tests are stored in the app and can be referenced and displayed at any time by simply logging into the app. Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. Scanwell financial results will be reported under the Integrated Diagnostic Solutions business within the Life Sciences segment. About the BD Veritor™ At-Home COVID-19 Test The BD Veritor™ At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Read More

HEALTH TECHNOLOGY

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics.Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs?Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely.Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779 Olga@GIANT.health

Read More

HEALTH TECHNOLOGY

Bright Health Group Expands Executive Team as It Drives Performance in Scaled Businesses

Bright Health Group | May 18, 2022

Bright Health Group, Inc. the first technology-enabled, Fully Aligned System of Care built for healthcare's consumer retail market,announced the expansion of its leadership team with the addition of Michael Carson as Bright HealthCare Chief Executive Officer and Jeff Cook as NeueHealth Chief Executive Officer. These proven leaders, reporting directly to Bright Health Group CEO Mike Mikan, will focus on leading the Company’s two complementary businesses, as Bright HealthCare has gained scale, and NeueHealth emerges as a differentiated market player. Carson will lead the Bright HealthCare business, which has reached scale, and will focus on driving core operational excellence, innovative consumer product and network solutions and profitable, sustainable growth. Carson brings deep experience across the payer and provider space, along with a passion for integrated and transformative healthcare innovation that drives better healthcare outcomes, experiences, and value. Most recently, Carson served as Chief Executive Officer of CareAbout, a multi-market, value-based primary and multi-specialty care start-up, and as President and Chief Executive Officer of Harvard Pilgrim Health Care, a leading not-for-profit health services company. Previously, Carson held leadership positions at Anthem, AmeriGroup, Blue Cross Blue Shield plans, and ConcertoHealth. Cook will lead NeueHealth, Bright Health Group’s personalized care delivery business, which has emerged as a differentiated market player. He will continue to grow and develop our Integrated Systems of Care. Throughout his career, Cook has consistently led initiatives that are at the forefront of value-based care and consumer-driven healthcare. Previously, Cook served as national Vice President of CVS Health HUBs, CVS’ suite of HUB clinical services. Prior to that, Cook served as the South Central Regional President of CVS Health/Aetna and held various leadership positions at Ascension Health and UnitedHealthcare. “Michael and Jeff both bring strong expertise in their respective domains, and most importantly, have a passion for and expertise in fully aligned, value-based care. As we embark on this next phase of Bright Health Group’s journey, we are excited to have these two phenomenal leaders join our already deep bench of talent within Bright HealthCare and NeueHealth.” Mike Mikan, President and CEO, Bright Health Group Sam Srivastava, current CEO of NeueHealth, will serve as a strategic advisor through the end of May to ensure a smooth transition. Jay Matushak, current Interim CEO of Bright HealthCare, will be returning to his previous role as CFO of Bright HealthCare, while taking on an expanded set of responsibilities. Said Mikan, “We want to thank Sam for his many contributions to Bright Health Group and Jay for stepping up to lead Bright HealthCare in the interim. Jay has done a terrific job progressing Bright HealthCare and we look forward to him partnering with Michael as they continue the build on our platform for change in healthcare.” About Bright Health Group Bright Health Group is the first technology-enabled, Fully Aligned System of Care built for healthcare's consumer retail market. Our differentiated approach aligns care delivery with the financing of care to drive better outcomes, lower costs, and enhance the consumer experience. We have two market-facing businesses: NeueHealth and Bright HealthCare. NeueHealth provides care delivery and value-based enablement services to over 500,000 value-based patients through our owned and affiliated clinics. Bright HealthCare offers Commercial and Medicare health plan products to over 1.1 million consumers across the nation. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together.

Read More

FUTURE OF HEALTHCARE

Ascensus Closes Newport Merger Agreement

Ascensus | April 11, 2022

Ascensus—whose technology and expertise help millions of people save for retirement, education, and healthcare—and Newport, the Walnut Creek, California-based retirement services provider—announced today that the two companies have closed their previously announced merger, the first step in their journey together as a combined organization. The union combines the capabilities and talents of two market leaders in tax-advantaged savings and related services, serving more than 15 million savers and overseeing more than $745 billion in assets under administration as of December 31, 2021. Together, the unified company employs more than 5,400 employees across the U.S. David Musto, president and chief executive officer of Ascensus, will serve as CEO of the combined company. Laura Ramanis, who has served as interim CEO of Newport since the announcement of the transaction last fall, and Kurt Laning, executive vice president of Newport Non-Qualified and Insurance Solutions, will join the Ascensus executive leadership team, reporting to Musto. "With today's announcement, Ascensus and Newport have taken an important step in our journey towards a stronger, unified company. Clients across our lines of business will benefit from our expanded capabilities—accelerated investments in technology, data analytics, and user experiences—and broadened expertise. And both Ascensus and Newport associates can look forward to new opportunities for personal growth and enhanced career development." Musto "Ascensus and Newport share a passion for helping people save for their futures and supporting the growth and success of our partners," said Ramanis. "We look forward to continuing that mission as a combined company." With industry-leading qualified and non-qualified retirement plan services, corporate and bank-owned life insurance (COLI and BOLI) practices, fiduciary and trust solutions, and other total rewards capabilities, Newport expands the services and expertise Ascensus provides to its clients and advisor partners. Newport's clients will benefit from greater access to unique tax-advantaged savings solutions across retirement, education, and health provided by Ascensus. The combined company's investments in technology, digital capabilities, and analytics will deliver enhanced value to clients, expand client relationships, and create even better outcomes for savers. Both the Ascensus and Newport brands remain in use at closing, with the Ascensus brand representing the unified company. "Our goal over the next several months is the successful unification of our company—built on the principle of 'best of the best' and our shared cultural attributes, and executed with the interests, quality, and stability of our client relationships foremost in mind," added Musto. "As a unified organization, Ascensus and Newport share a strong commitment to serving our clients and offering more—across the tax-advantaged retirement, education, and health savings expertise for which Ascensus is known, and capitalizing on Newport's well-established qualified and non-qualified retirement services, and fiduciary and COLI/BOLI capabilities as well." Evercore acted as exclusive financial advisor to Newport in connection with the transaction. Goldman Sachs Bank USA, SPC Financing Company LLC, and KKR Capital Markets LLC led the financing consortium. Simpson Thacher & Bartlett LLP acted as transactional counsel to Ascensus and Kirkland & Ellis LLP acted as financing counsel to Ascensus. Morgan Lewis & Bockius LLP acted as legal counsel to Newport. About Ascensus Ascensus helps millions of people save for what matters—retirement, education, and healthcare. Through co-branded, private-labeled, and other governmental partnerships, our technology, market insights, and business knowledge enhance the growth and success of our partners, their clients, and savers. Ascensus is a leading recordkeeping services provider, third-party administrator, and government savings facilitator in the United States. About Newport Headquartered in Walnut Creek, California, Newport is a leading retirement services provider that helps employers—and the advisors who serve them—prepare employees for a more financially secure retirement. The company has more than $150 billion in retirement assets under administration and more than $300 billion in corporate retirement and insurance assets. Newport maintains investment objectivity, fee transparency and a commitment to flexible, responsive service. Staffed by an exceptional team of nearly 1,500 retirement, insurance, and consulting professionals, the company provides retirement solutions tailored to the needs of employers of every size, from small businesses to the Fortune 1000.

Read More